About Us
iSTAT Therapeutics is breaking resistance to cancer immunotherapy
By eliminating the “master brake" engaged by the tumor in multiple types of immune cells, iSTAT's novel platform of bi-modal oligonucleotide drugs overcomes a key hurdle in achieving effective immunotherapy treatments across a variety of cancer types, independently of their genetic differences.